Anaphylaxis: getting to the point (and price) of diagnosis and treatment

Ronald B Moss Adamis Pharmaceuticals Corporation, San Diego, CA, USA Anaphylaxis was first described by Charles Richet and Paul Portier in 1901 as an immune reaction that is the opposite of immune protection resulting from vaccination.1 Anaphylaxis can be better categorized into both immunoglobulin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of asthma and allergy 2018-01, Vol.11, p.109-110
Main Author: Moss, Ronald B
Format: Article
Language:English
Subjects:
Anaphylaxis
Bronchial spasm
Bronchospasm
Care and treatment
Diagnosis
Drugs
Epinephrine
Evidence-based medicine
Hives (Disease)
Hypotension
Immunoglobulin E
Immunoglobulins
Immunosuppressive agents
Itching
Medical diagnosis
n/a
Pruritus
Risk factors
Urticaria
Vaccination
Venoms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ronald B Moss Adamis Pharmaceuticals Corporation, San Diego, CA, USA Anaphylaxis was first described by Charles Richet and Paul Portier in 1901 as an immune reaction that is the opposite of immune protection resulting from vaccination.1 Anaphylaxis can be better categorized into both immunoglobulin E (IgE) and non-IgE pathways.2 Between 1.6% and 5.1% of the Americans are estimated to experience anaphylaxis, which can be fatal.3 The common triggers for an acute anaphylactic episode are foods, drugs, and venoms. Ultimately, a number of mediators are released that explain the clinical symptoms of flushing, pruritus, urticaria, shortness of breath, bronchospasm, hypotension, and cardiovascular collapse.2 Epinephrine injection is the evidence-based treatment for acute anaphylaxis, and delayed epinephrine administration is a risk factor for fatal anaphylaxis.3 However, like many other effective therapies in medicine, there remain barriers to treatment of anaphylaxis.
ISSN:1178-6965
1178-6965
DOI:10.2147/JAA.S170650